Earnings
-
Protected: Solazyme: On track for commercialization
.
There is no excerpt because this is a protected post.
-
Protected: Amyris: Weak results, fair progress
.
There is no excerpt because this is a protected post.
.
There is no excerpt because this is a protected post.
.
There is no excerpt because this is a protected post.